M0247 — Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
M0247 is a HCPCS Level II code for intravenous infusion, sotrovimab, includes infusion and post administration monitoring. It belongs to the Medical Services section. It was terminated on December 12, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated M0247 on December 12, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for M0247
- Long descriptor
- Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
- Short descriptor
- Sotrovimab infusion
- Added
- May 26, 2021
- Terminated
- December 12, 2024
- BETOS
- O1G
- Pricing indicator
- 54 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Vaccinations.
Codes adjacent to M0247
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If M0247 is not quite right, the correct code is very often within a few positions of it.
- M0238Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
- M0239Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoringterminated
- M0240Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat dosesterminated
- M0241Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat dosesterminated
- M0243Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoringterminated
- M0244Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergencyterminated
- M0245Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoringterminated
- M0246Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergencyterminated
- M0248Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergencyterminated
- M0249Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
- M0250Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
- M0300Iv chelation therapy (chemical endarterectomy)
- M0301Fabric wrapping of abdominal aneurysm
- M1000Pain screened as moderate to severeterminated
- M1001Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinicianterminated
- M1002Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not giventerminated
Questions about M0247
What is HCPCS code M0247?
M0247 is a HCPCS Level II code for intravenous infusion, sotrovimab, includes infusion and post administration monitoring. It sits in the Medical Services section.
Does Medicare cover M0247?
The CMS HCPCS file marks M0247 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is M0247 still valid?
No. M0247 was terminated on December 12, 2024 and should not be used on new claims.